Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis

Objective Canakinumab is a human anti–interleukin‐1β (anti–IL‐1β) blocking agent that effectively neutralizes IL‐1β–mediated signaling for treatment of systemic juvenile idiopathic arthritis (JIA). While many patients have dramatic clinical response to IL‐1 blockade, approximately one‐third fail to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2021-07, Vol.73 (7), p.1334-1340
Hauptverfasser:	Verweyen, Emely L., Pickering, Alex, Grom, Alexei A., Schulert, Grant S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Arthritis Blood CD163 antigen Complications Criteria DNA microarrays Gene expression Genes Interferon Interleukins Leukocytes (neutrophilic) Monoclonal antibodies Patients Random variables Secondary analysis Signatures Transcriptomes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!